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Abstract
Background: Streptococcus pneumoniae causes a broad spectrum of illnesses ranging from mild upper respiratory
tract infections to invasive pneumococcal disease (IPD). Quantitative data on the burden of pneumococcal disease,
important for the establishment of appropriate vaccination strategies, is currently lacking in adults.
Methods: This multicenter, retrospective cohort study was designed to estimate the clinical and economic burden
of IPD in adults over the last decade. Data were collected from patients with IPD at 10 university hospitals in South
Korea. We estimated the proportion of IPD among all hospitalized patients, the case fatality rate, and the direct
medical costs of IPD. Data were further analyzed according to age and risk groups.
Results: During the study period, 970 patients with IPD were identified. The mean age for all patients was 60.9
years; patients aged 50–64 years (33.0%) were most numerous, followed by those aged 65–74 years (27.4%). Overall,
the proportion of IPD was 0.36 cases/1000 hospitalized patients and the case fatality rate was 30.9%, which
increased significantly with age (p < 0.01). The mean direct medical costs were estimated to be US $7,452 without
a difference between age and risk groups. On multivariate analysis, old age, advanced ECOG performance status,
bacteremic pneumonia, and nosocomial infection were independent risk factors of 30-day case fatality.
Conclusions: The clinical disease burden of IPD increased significantly with age and direct medical costs from IPD
were substantial, regardless of age and co-morbid conditions. The current age-based vaccination strategy appears
to be appropriate.
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Background
Streptococcus pneumoniae causes a broad spectrum of
illnesses ranging from mild upper respiratory tract infec-
tion to severe invasive disease. Of all the manifestations,
invasive pneumococcal disease (IPD) is associated with a
particularly high case fatality rate and economic cost. Al-
though the incidence of IPDs has decreased in recent
years with the introduction of the 7-valent pneumo-
coccal conjugate vaccine (PCV7), the WHO has estima-
ted that 1.6 million deaths are caused by pneumococci
annually [1]; this estimate included the deaths of 0.7–1
million children aged less than 5 years, accounting for
about 11% of all deaths in children aged 1–59 months
[2]. In the United States, IPD was responsible for 22,000
deaths, 4 million disease episodes, and direct medical
care costs of $3.5 billion in 2004 [3]. In this study, most
of the deaths and medical costs were found to be associ-
ated with adult patients despite their accounting for only
half of the disease episodes [3]. In adults, data on dis-
ease burden need to be further investigated with res-
pect to age, underlying comorbidities, and performance
status. These data could be useful in revising vaccination
strategies.
Currently, both the 23-valent pneumococcal polysac-
charide vaccine (PPV23) and PCV13 have been used for
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vaccination of adults. PPV23 is recommended for all
adults aged ≥65 years and for adults at high risk who are
aged 19–64 years [4]. A one-time revaccination dose of
PPV23 is recommended 5 years after the first dose for
asplenic or immunocompromised persons. In addition
to PPV23, PCV13 was licensed for the prevention of
IPD and pneumonia in adults aged ≥50 years [4]. PCV13
has been licensed for use in adults solely on the basis of
immunogenicity data, and a clinical trial is underway to
evaluate the efficacy of PCV13 against pneumococcal
pneumonia in adults.
Despite the wide availability of pneumococcal vaccines,
vaccination rates around the world remain suboptimal in
adults (less than 50% even in high-risk groups) [5-7].
Among South Korean children, the PCV7 coverage rate
increased up to 72% in 2009 [8], while the uptake rate in
high-risk adults was very low (0.6%), according to a na-
tionwide survey in South Korea [9]. Insufficient data on
the burden of pneumococcal disease might be a barrier
to increased immunization rates among the South
Korean adults.
This study was designed to estimate the proportion of
IPD among all hospitalized patients, the case fatality
rate, and the direct medical costs associated with IPD in
South Korean adults over the last decade. In order to
better clarify IPD disease burden in adults, data were
analyzed by age and risk group.
Methods
Study design and subjects
This retrospective cohort study included all patients with
IPD at 10 university hospitals in South Korea between
January 1, 2001 and September 30, 2011. To obtain data
representative of the entire nation, participating hospitals
were selected on the basis of geographic location and
population served. We included hospitals only if all data
were available regarding direct medical costs. All IPD
cases among Korean adults aged ≥18 years were included.
Available data were stratified according to age and risk
group and analyzed to determine the proportion of IPD
(cases/1000 hospitalized patients), distribution of primary
infection sites, case fatality rate, length of hospital stay,
and direct medical costs. Total annual hospital admissions
were obtained from an electronic database system. We
also aimed to evaluate the change in the proportion of pa-
tients with IPD and the case fatality rate after introduction
of the PCV7 vaccine during the study period.
All cases that met the IPD definition were selected
from microbiological databases. The patients’ medical re-
cords were reviewed to determine age, sex, comorbidities,
Eastern Cooperative Oncology Group (ECOG) perform-
ance status, date of admission, primary site of infection,
intensive care unit (ICU) admission, duration of hospi-
talization, and 30-day case fatality. The case fatality rate
was estimated among patients whose survival or death
was recorded. Direct medical costs were captured from in-
formation on resource use contained in the medical re-
cords (consultations, prescriptions, and procedures). This
research was performed with approval from the institu-
tional review boards of the selected 10 university hospitals.
Written consent was waived by the institutional review
board, because of the retrospective nature of the study and
because patients' private information was not included.
Definitions
IPD was defined as the isolation of S. pneumoniae from
a normally sterile site, such as blood, cerebrospinal fluid
(CSF), and pleural or ascites fluid. Each patient was clas-
sified into one of three groups based on underlying
medical conditions: high-risk (those advised to receive
PPV23 vaccination every five years), moderate-risk
(those requiring a single dose vaccination in their life),
and low-risk (those who are not recommended to re-
ceive pneumococcal vaccination). High risk was defined
by the presence of one or more of the following: (1)
splenic dysfunction including post-splenectomy status,
(2) hematologic malignancy such as multiple myeloma,
leukemia, or lymphoma, (3) a condition affecting the
bone marrow or lymphatic system, such as chemother-
apy with alkylating drugs or antimetabolites, or radiation
within the previous 3 months, (4) solid organ or stem
cell transplantation, (5) chronic renal disease such as
nephrotic syndrome or chronic renal failure, (6) HIV in-
fection, (7) high-dose corticosteroid use (≥20 mg/day of
prednisone or equivalent) lasting two or more weeks, or
(8) treatment with a recombinant human immunomodu-
lator, such as rituximab, adalimumab, or infliximab.
Moderate risk was defined by one or more of the follow-
ing: (1) diabetes mellitus, (2) chronic liver disease, (3)
chronic pulmonary disease, such as asthma or chronic
obstructive lung disease, (4) chronic cardiovascular dis-
ease, such as heart failure, cardiomyopathy, or other
chronic condition affecting cardiac function, (5) current
smoking, or (6) heavy alcohol use, which was defined as
alcohol use for more than 5 days a week or having a
diagnosis of alcoholism. Low risk was assigned to condi-
tions that did not satisfy criteria for high or moderate
risk. IPD was defined as a nosocomial infection if the
first positive culture was obtained more than 48 hours
after hospital admission or if the patient had been hospi-
talized for more than 2 of 7 days before the first positive
culture. Recurrent infection in a patient was defined as
two or more IPD episodes within a 12-month period.
Calculation of direct medical costs for invasive
pneumococcal disease
The direct medical costs of IPD were extracted from
the hospital financial database, which included both
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outpatient and inpatient costs: hospitalization expen-
ditures, nursing, IPD-related prescription drugs, examin-
ation fees, etc. These were inflated to reflect 2011 prices.
To capture direct medical costs only, we used the follow-
ing approach. To estimate hospitalization costs, we ex-
cluded from the calculation (1) nosocomial IPD cases that
occurred during hospitalization at the 10 study hospitals,
and (2) costs from day 1 of the onset of comorbidity to
the last day of hospitalization (if any comorbidity devel-
oped during the entire hospitalization period). Infectious
disease specialists in each hospital reviewed all the medical
records to find new comorbidities that required surgical/
medical treatment unrelated to IPD. With respect to
outpatient visits, we included outpatient costs for me-
dications and procedures that were IPD-related. The es-
timated costs of disease were calculated in Korean won
(KRW) and converted into US dollars at a rate of
KRW1200=US$1.
Antibiotic susceptibility test
Antibiotic susceptibility was tested in accordance with
Clinical Laboratory Standards (CLSI) guidelines at each
hospital [10]. Cases with available minimal inhibitory
concentration (MIC) results were included in the analysis
of antibiotic susceptibility. Interpretive breakpoints for
penicillin (non-meningitis S. pneumoniae isolates), ≤2 μg/
mL (susceptible), 4 μg/mL (intermediate), and ≥8 μg/mL
(resistant); and for erythromycin, ≤0.25 μg/mL (suscep-
tible), 0.25<MIC≤1 μg/mL (intermediate), and > 1 μg/mL
(resistant).
Statistical analysis
We performed descriptive analyses and comparisons to
examine demographics, clinical characteristics, and IPD
disease burden based on age and risk group. Data were
expressed as the mean ± standard deviation and were
analyzed using SPSS version 10.0 (SPSS Inc., Chicago,
IL, USA). Chi-square tests were carried out to compare
categorical variables. For continuous variables, either stu-
dent‘s t-test or one-way analysis of variance (ANOVA)
was performed with Tukey’s method for multiple compari-
sons. A p-value < 0.05 was considered statistically signi-
ficant. Using a logistic regression model, multivariate
analysis was carried out to identify independent risk fac-
tors for 30-day case fatality.
Results
Demographic and clinical characteristics of invasive
pneumococcal disease
Nine hundred seventy patients with IPD were identified
during the study period, including 264 (27.2%) at high
risk, 423 (43.6%) at moderate risk, and 283 (29.2%) at
low risk. The mean age of patients was 60.9 years. Pa-
tients aged 50–64 years were most numerous (33.0%),
followed by those aged 65–74 years (27.4%), 18–49 years
(22.2%), and 75 years and older (17.4%). The demo-
graphic and clinical characteristics of patients with IPD
are presented in Table 1. The age groups differed signifi-
cantly in gender ratio, alcohol use, smoking, ECOG per-
formance status, risk group distribution, and underlying
conditions. Male sex, heavy alcohol use, and current
smoking were common in the group aged 18–49 and in
the group aged 50–64 years, while the proportion with
ECOG performance status grade 4 increased with age.
Patients at high and moderate risk were most numerous
in the group aged 50–64 years. Chronic pulmonary,
cardiovascular, cerebrovascular, and neurodegenerative
diseases, and conditions such as multiple myeloma in-
creased in prevalence with age. The proportion of pa-
tients with diabetes mellitus increased significantly by
age 50 (p < 0.01), while chronic liver disease was more
common in the younger age groups (18–49 years and
50–64 years, p < 0.01). Patients receiving chemotherapy
were predominantly in the two groups aged 50–64 and
65–74 years (p < 0.01).
In assessing clinical presentation according to age,
bacteremic pneumonia and empyema were more com-
mon in adults 65 years of age and older than in younger
adults, while meningitis and peritonitis were more com-
mon in the younger groups (p < 0.01) (Table 1). Patients
were hospitalized after a mean of 3.5 days from symp-
tom onset. Recurrent infection was rare (0.8%) irrespec-
tive of age group.
The proportion of IPD acquired at either a long-term
care facility or tertiary referral hospital increased signifi-
cantly with increasing patient age (p < 0.01). Overall,
18.1% of the infections were nosocomial, increasing to
19.2% in subjects aged 65–74 years, and to 27.2% in sub-
jects aged 75 years and older.
Disease burden of invasive pneumococcal disease
Overall, the proportion of hospitalized patients with IPD
was 0.36 cases/1000 hospitalized, and the case fatality
rate was 30.9%, which increased significantly with age
(p < 0.01) (Table 1). However, the direct medical costs
per case of IPD did not differ between age groups (mean
cost US $7,452/case; p = 0.11) (Table 1).
Table 2 shows the clinical and economic burden asso-
ciated with invasive pneumococcal disease. Stratification
according to risk group revealed no significant differ-
ences in the duration of hospitalization (22.0 days vs.
17.8 days vs. 19.0 days, p = 0.47), case fatality rate
(35.3% vs. 27.7% vs. 31.5%, p = 0.28), and direct medical
cost per case (mean, US$ 7,667 vs. US$ 7,037 vs. US$
7,903; p = 0.58) among the three risk groups (high risk
vs. moderate risk vs. low risk). However, both the rate of
admission and the duration of stay in the intensive care
unit (ICU) were higher in the low- and moderate-risk
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Age, mean±SD 60.9±15.0 38.8±7.9 58.2±4.1 69.3±2.7 81.0±4.4 < 0.01
Risk group, no. (%) < 0.01
High risk 264 (27.2) 38 (17.7) 112 (35.0) 86 (32.3) 28 (16.6)
Moderate risk 423 (43.6) 91 (42.3) 147 (45.9) 108 (40.6) 77 (45.5)
Low risk 283 (29.2) 86 (40.0) 61 (19.1) 72 (27.1) 64 (37.9)
Sex (male), no. (%) 673 (69.4) 139 (64.7)a 237 (74.1)b 191 (71.8)b 106 (62.7)a 0.02
ECOG performance status grade 4, no. (%) 89 (9.2) 10 (4.7)a 19 (5.9)a 27 (10.2)b 33 (19.5)c < 0.01
Heavy alcoholic, no. (%)* 99 (10.2) 32 (14.9)a 46 (14.4)a 14 (5.3)b 7 (4.1)b < 0.01
Current smoker, no. (%) 171 (17.6) 46 (21.4)a 60 (18.8)a 48 (18.0)a 17 (10.1)b 0.03
Comorbid condition, no. (%) 630 (64.9) 95 (44.2)a 235 (73.4)b 188 (70.7)b 112 (66.3)b < 0.01
Splenic dysfunction 8 (0.8) 4 (1.9) 1 (0.3) 3 (1.1) 0 (0) 0.14
Multiple myeloma 38 (3.9) 2 (0.9)a 23 (7.2)b 10 (3.8)b 3 (1.8)ab < 0.01
Other hematologic malignancy 26 (2.7) 7 (3.3)a 8 (2.5)b 8 (3.0)b 3 (1.8)a 0.81
Chemotherapy 163 (16.8) 18 (8.4) 74 (23.1) 55 (20.7) 16 (9.5) < 0.01
Solid organ/stem cell transplantation 6 (0.6) 3 (1.4) 2 (0.6) 0 (0) 1 (0.6) 0.29
Long-term steroid therapy 11 (1.1) 4 (1.9) 3 (0.9) 2 (0.8) 2 (1.2) 0.69
Chronic renal failure 54 (5.6) 9 (4.2) 20 (6.3) 17 (6.4) 8 (4.7) 0.65
Nephrotic syndrome 2 (0.2) 1 (0.5) 1 (0.3) 0 (0) 0 (0) 0.62
HIV infection 1 (0.1) 0 (0) 0 (0) 1 (0.4) 0 (0) 0.45
Diabetes mellitus 206 (21.2) 23 (10.7)a 78 (24.4)b 60 (22.6)b 45 (26.6)b < 0.01
Chronic liver disease 133 (13.7) 31 (14.4)a 71 (22.2)b 23 (8.6)c 8 (4.7)c < 0.01
Chronic pulmonary disease 81 (8.4) 4 (1.9)a 23 (7.2)b 25 (9.4)b 29 (17.2)c < 0.01
Chronic cardiovascular disease 76 (7.8) 9 (4.2)a 17 (5.3)a 22 (8.3)a 28 (16.6)b < 0.01
Cerebrovascular disease 58 (6.0) 9 (4.2)a 12 (3.8)a 23 (8.6)b 14 (8.3)ab 0.03
Neurodegenerative disease 14 (1.4) 0 (0)a 2 (0.6)a 5 (1.9)ab 7 (4.1)b < 0.01
Neuromuscular disease 9 (0.9) 2 (0.9) 2 (0.6) 2 (0.8) 3 (1.8) 0.37
Clinical presentation, no. (%)
Primary bacteremia 190 (19.6) 40 (18.6)ab 75 (23.4)a 55 (20.7)a 20 (11.8)b 0.02
Bacteremic pneumonia 538 (55.5) 102 (47.4)a 160 (50.0)a 150 (56.4)a 126 (74.6)b < 0.01
Empyema 49 (5.1) 4 (1.9)a 14 (4.4)a 25 (9.4)b 6 (3.6)a < 0.01
Meningitis 84 (8.7) 35 (16.3)a 21 (6.6)b 20 (7.5)b 8 (4.7)b < 0.01
Peritonitis 74 (7.6) 23 (10.7)a 33 (10.3)a 13 (4.9)b 5 (3.0)b < 0.01
Septic arthritis 13 (1.3) 1 (0.5) 5 (1.6) 3 (1.1) 4 (2.4) 0.42
Infective endocarditis 2 (0.2) 1 (0.5) 1 (0.3) 0 (0) 0 (0) 0.62
Time from symptom onset to admission (days),
mean±SD
3.5±8.5 4.0±9.0 2.8±4.7 4.1±12.5 2.9±4.6 0.22
Recurrent infection, no. (%) 8 (0.8) 2 (0.9) 5 (1.6) 1 (0.4) 0 0.24
Site of acquisition of infection, no. (%) < 0.01
Community 794 (81.9) 191 (88.8) 265 (82.8) 215 (80.8) 123 (72.8)
Long-term care facility 42 (4.3) 4 (1.9) 7 (2.2) 7 (2.6) 24 (14.2)
Tertiary referral hospital 134 (13.8) 20 (9.3) 48 (15.0) 44 (16.6) 22 (13.0)
Proportion of IPD (cases/1,000 hospitalized patients) 0.36 0.21a 0.39b 0.49c 0.69d < 0.01
Case fatality rate, no. (%)† 281/909 (30.9) 38/207 (18.4)a 83/309 (26.9)a 86/243 (35.4)b 74/150 (49.3)c < 0.01
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groups compared to the high-risk group (p < 0.01 and
p = 0.05, respectively) reflecting aggressive therapy in
previously healthy subjects. On further analysis by age in
each risk group, the case fatality rate tended to signifi-
cantly increase with age in the high- and low-risk groups
(p < 0.01). Direct medical costs differed by age only in
the moderate-risk group; costs were higher in patients
aged 50–64 years compared to the others (p = 0.03)
(Table 2).
Prognostic factors of invasive pneumococcal disease
On univariate analysis, older age, advanced ECOG per-
formance status, bacteremic pneumonia, and nosocomial
infection were associated with a higher 30-day case fatal-
ity rate (p < 0.05). Risk group (p = 0.12), sex (p = 0.08),
and antibiotic susceptibility (penicillin, p = 0.28; erythro-
mycin, p = 0.73) did not influence the 30-day case fata-
lity rate. Meningitis was associated with a lower case
fatality rate (p < 0.01). On multivariate analysis, old age
(odds ratio, 1.02; 95% CI 1.01-1.03), ECOG performance
status grade 4 (odds ratio, 5.97; 95% CI 3.30-10.80),
bacteremic pneumonia (odds ratio, 1.53; 95% CI 1.10-
2.14), and nosocomial infection (odds ratio, 2.21; 95% CI
1.49-3.25) were independent risk factors for 30-day case
fatality (Table 3).
Trends in proportion, case fatality rate, and antibiotic
susceptibility
Over the study period, the proportion of IPD among
hospitalized patients (cases/1000), the case fatality rate,
and the antibiotic susceptibility rate were serially esti-
mated (Figure 1). Since the introduction of PCV7 in
2003, the proportion of IPD and case fatality rates did
not change remarkably. However, rates of penicillin and
erythromycin susceptibility decreased in the years lead-
ing up to and after 2010: 100% (2008), 96.8% (2009),
91.3% (2010) and 89.5% (2011) for penicillin; 37.7%
(2008), 32.7% (2009), 32.4% (2010) and 29.1% (2011) for
erythromycin.
Discussion
Although the global burden of IPD is described exten-
sively in the literature, most studies focus on pediatric
diseases, and currently available data for Asian countries
is lacking. This multicenter study evaluated the IPD
disease burden based on laboratory-confirmed cases in
adults, stratified by age and underlying conditions. Di-
rect medical costs were estimated by an objective,
concrete method to avoid overestimation. These re-
sults may be useful for evaluating the cost-effectiveness of
pneumococcal vaccines in the future.
Consistent with previous studies [11-13], the propor-
tion of IPD among hospitalized patients and the IPD
case fatality rate increased with age. Though patients
aged 65 years and older may be more likely to develop
IPD compared to younger patients, those aged 50–64
years comprised the largest percentage in this study. A
majority of patients aged 50–64 years (73.4%, 239 among
320 subjects) had comorbidities such as diabetes and
chronic lung or cardiovascular diseases. Weycker et al.
[13] previously found that persons aged 50–64 years
comprised the largest proportion of the IPD patients.
Considering that this age group is most active socially,
indirect medical costs may be greater than correspond-
ing costs for the elderly. In addition, Weycker et al. [13]
reported that the majority of pneumococcal diseases
(≥60%), pneumococcal-related death, and pneumococcal-
related costs were accounted for by high-risk cases. The
high-risk group may be also at greatest risk for IPD. How-
ever, contrary to the study by Weycker et al. [13], the
moderate-risk group in our study accounted for more
than 40% of IPD cases. Pneumococcal vaccination for the
group at moderate risk should be emphasized.
It is also noteworthy that even the low-risk group
presented a substantial clinical and economic burden.
This may be related to the presence of underlying cere-
brovascular, neurocognitive, and neuromuscular disor-
ders and poor performance status in this group of
patients. Jain et al. reported that patients with neurologic
diseases are at high risk for pneumonia after influenza
Table 1 Baseline patient characteristics and disease burden of invasive pneumococcal disease, stratified by age group
(Continued)
Direct medical costs per case‡ 0.11
Mean (95% CI) US $7,452 US $6,223 US $8,191 US $7,910 US $6,956
(6,816-8,088) (5,218-7,229) (6,963-9420) (6,645-9,175) (5,351-8,561)
Median (IQR) US $4,772 US $4,092 US $5,095 US $5,320 US $4,439
(2,378-8,698) (2,364-7,844) (2,898-9,018) (2,796-10,590) (1,844-8,136)
ECOG, Eastern Cooperative Oncology Group; IQR, inter-quartile range.
NOTE: The same letters (alphabetical superscripts) indicate non-significant differences between groups based on either Tukey’s multiple comparison tests or
chi-square tests.
* Defined as alcohol use for more than 5 days a week or having a diagnosis of alcoholism.
†Case fatality rates were based only on patients whose survival or death was confirmed.
‡KRW1200=US$1.
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infection [14]. Though currently not considered high
priority for pneumococcal vaccination, patients with neu-
rologic disease were at great risk for IPD. Moreover, sev-
eral studies have shown that neurologic diseases are risk
factors for mortality after pneumococcal infection [15,16].
This suggests that the definitions for low, moderate, and
high risk groups should be reconsidered.
Similar to the findings of Weycker et al. [13], the di-
rect medical costs per case did not differ significantly
between the risk or age groups in the present study;
Table 2 Burden of invasive pneumococcal disease, stratified by risk group
High-risk group p-value
Total (n=264) 18-49 Years (n=38) 50-64 Years (n=112) 65-74 Years (n=86) ≥75 Years (n=28)
Duration of hospitalization 20.1±19.3 22.0±16.5 21.7±21.9 17.3±14.4 19.4±24.2 0.41
ICU admission, no. (%) 84 (31.8) 13 (34.2) 33 (29.5) 28 (32.6) 10 (35.7) 0.9
Duration of ICU admission 3.4±8.7 3.2±7.2 2.7±6.2 3.1±7.5 6.7±17.8 0.19
Case fatality rate, no. (%)* 89/252 (35.3) 8/38 (21.1)a 33/107 (30.8)a 30/82 (40.0)a 18/25 (72.0)b < 0.01
Time to death (days) 9.7±8.5 9.6±5.9 10.6±9.1 8.6±7.9 9.7±9.9 0.85
Direct medical costs per case† 0.76
Mean (95% CI) US $7,667 US $6,990 US $7,135 US $8,609 US $7,880
(6,395-8,938) (4,464-9,516) (5,746-8,524) (5,648-11,569) (2,297-13,462)
Median (IQR) US $5,552 US $6,749 US $5,612 US $5,472 US $3,262
(2,567-9,872) (2,474-9,948) (3,007-9,650) (3,278-10,442) (1,532-10,034)
Moderate-risk group p-value
Total (n=423) 18-49 years (n=91) 50-64 years (n=147) 65-74 years (n=108) ≥75 years (n=77)
Duration of hospitalization 17.8±26.1 15.3±15.7 17.7±17.3 19.0±24.4 19.0±45.3 0.76
ICU admission, no. (%) 191 (45.2) 35 (38.5) 68 (46.3) 46 (42.6) 42 (54.5) 0.19
Duration of ICU admission 5.3±20.8 3.2±6.4 5.2±10.9 4.7±8.9 9.0±44.9 0.33
Case fatality rate, no. (%)* 110/397 (27.7) 19/88 (21.6) 37/144 (25.7) 28/96 (29.2) 26/69 (37.7) 0.14
Time to death (days) 7.4±6.8 6.3±5.3 8.8±7.7 7.1±6.1 6.5±6.9 0.45
Direct medical costs per case† 0.03
Mean (95% CI) US $7,037 US $5,404a US $8,756b US $6,964ab US $5,730a
(6,120-7,955) (4,191-6,617) (6,650-10,861) (5,395-8,532) (4,423-7,037)
Median (IQR) US $4,517 US $3,685 US $4,956 US $4,664 US $4,679
(2,432-7,961) (2,405-6,805) (2,797-10,003) (2,402-9,499) (1,879-7,057)
Low-risk group p-value
Total (n=283) 18-49 years (n=86) 50-64 years (n=61) 65-74 years (n=72) ≥75 years (n=64)
Duration of hospitalization 19.0±25.6 19.0±20.9 21.9±21.2 19.9±27.4 15.4±32.3 0.55
ICU admission, no. (%) 139 (49.1) 33 (38.4) 31 (50.8) 40 (55.6) 35 (54.7) 0.11
Duration of ICU admission 6.8±13.8 5.9±13.6 8.3±14.3 6.8±13.1 6.8±14.7 0.78
Case fatality rate, no. (%)* 82/260 (31.5) 11/81 (13.6)a 13/58 (22.4)a 28/65 (43.1)b 30/56 (53.6)b < 0.01
Time to death (days) 7.9±9.0 10.2±15.4 9.2±10.3 9.3±8.1 5.3±5.2 0.26
Direct medical costs per case† 0.69
Mean (95% CI) US $7,903 US $6,849 US $8,528 US $8,557 US $8,090
(6,675-9,131) (4,931-8,766) (5,715-11,342) (6,239-10,875) (4,727-11,453)
Median (IQR) US $4,968 US $4,448 US $5,726 US $5,896 US $3,367
(2,187-9,613) (1,856-8,574) (3,443-8,858) (2,178-11,733) (1,879-9,308)
IQR, inter-quartile range.
NOTE: The same letters (alphabetical superscripts) indicate non-significant differences between groups based on either Tukey’s multiple comparison tests or
chi-square tests.
* Case fatality rates were based only on patients whose survival or death was confirmed.
†KRW1200=US$1.
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however, our estimates (mean, US$ 5,404-8,756/case)
were much lower than those reported by Weycker et al.
(US$ 15,402-31,849/case). First, this difference may be
related to the methods used for estimation. Weycker
et al. [13] estimated the direct medical costs based on
data from the 2004 Healthcare Cost and Utilization Pro-
ject (HCUP) Nationwide Inpatient Sample (NIS) using
mean age- and risk-specific charges, while we calculated
them by adding only IPD-related costs for each patient.
Second, direct medical costs may potentially be affected
by the healthcare system and geographic factors that
affect accessibility. In a US study by Huang et al. [3],
mean direct costs per case of pneumococcal bacteremia
was estimated to be US $12,667, which is also higher
than our estimates.
The patients’ clinical presentations varied significantly
by age and risk group. Primary bacteremia was common
in the high-risk group, bacteremic pneumonia and peri-
tonitis were most common in the moderate-risk group,
and meningitis was prominent in the low-risk group.
Bacteremic pneumonia or empyema was more common
in older patients, while meningitis and peritonitis were
more common in the younger adults. These differences
may be related to host-specific serotype distributions,
host immunity, or other factors. Previous reports sho-
wed that some serogroups with high IPD potential (1, 5
and 7) affected relatively healthy adults, while those with
low or intermediate IPD potential (3, 6, 8, 15, 19, 23, 33
and 38) were more likely to affect individuals with
immunocompromise due to age and/or comorbidity
[17,18]. Serotypes 3 and 19A pneumococci are more
likely to cause pneumonia/empyema [19], while Serotype
1 is known to cause pneumonia and peritonitis in young
adults [20].
In this study, the overall case fatality rate (30.9%) was
higher than in previous reports, which may reflect that
the study was composed exclusively of adults. Similarly
in a previous Korean study, the case fatality rate for bac-
teremic pneumonia was 28.6% in adults [16]. In contrast,
the case fatality rates for children were reported to be
lower than 15% [21]. Independent risk factors for 30-day
case fatality include advanced age, poor performance sta-
tus, bacteremic pneumonia, and nosocomial infection.
The case fatality in this study was not related to primary
bacteremia, but to bacteremic pneumonia. Previous stu-
dies reported advanced age, male sex, comorbidities,
alcoholism, sepsis, and meningitis as risk factors for
mortality [17,19]. In this study, meningitis was not re-
lated to survival, contrary to previous studies. This may
be related to the age of the study population. The risk of
Figure 1 Trends in invasive pneumococcal disease (IPD): proportion of IPD, case fatality rate, and antibiotic susceptibility.
Table 3 Prognostic factors related to 30-day mortality
among patients with invasive pneumococcal disease
Variables 0dds ratio 95% Confidence interval
Age 1.02 1.01-1.03
Sex (male) 1.17 0.83-1.65
ECOG performance status: reference category, grade 0
Grade 1 1.09 0.73-1.63
Grade 2 1.1 0.68-1.78
Grade 3 1.42 0.85-2.39
Grade 4 5.97 3.30-10.80
Risk group: reference category, low-risk group
Moderate risk 0.87 0.81-1.87
High risk 1.23 0.59-1.27
Bacteremic pneumonia 1.53 1.10-2.14
Meningitis 0.57 0.27-1.21
Nosocomial infection 2.21 1.49-3.25
ECOG, Eastern Cooperative Oncology Group.
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meningitis is much higher in pediatric patients than in
adults, and infants under one year of age have an espe-
cially high case fatality rate [19].
Since the introduction of the PCV7 vaccine in 2003, a
substantial decline in IPD incidence has been reported
in the target population aged 5 years and younger [22].
In a study conducted in the Netherlands, however, the
overall IPD incidence remained constant in adults [23].
With a serotype shift under the vaccine pressure, the
PCV7 coverage rate fell below 25% in Korean patients
with pneumococcal pneumonia irrespective of age (un-
published data). Likewise, the proportion of hospitalized
adult patients with IPD and the adult case fatality rate
did not decrease remarkably over this decade according
to this study. Interestingly, the rates of bacterial suscep-
tibility to penicillin and erythromycin decreased around
2010, which may be related to the expansion of the
multidrug-resistant serotype 19A [11,24,25].
This study has several limitations. First, we could not
estimate the incidence of IPD because the study popula-
tions were highly mobile and IPD patients were referred
from diverse areas of Korea. Second, the serotype distri-
bution could not be investigated. Third, this study was
conducted retrospectively, introducing a potential infor-
mation bias. Uncontrolled confounding factors might
exist. To minimize these factors, well-trained research
nurses collected data in each hospital using a structured
case report form. All data were reviewed and processed
without patient-identifying information at the data ma-
nagement center under the supervision of a medical
advisor.
Conclusion
In conclusion, we investigated the clinical and economic
burden of IPD in adults. The proportion of IPD among
hospitalized patients and the case fatality rate increased
significantly with age, and direct medical costs were high
regardless of age and comorbid conditions. The current
age-based vaccination strategy appears appropriate, how-
ever, given the results of these studies. Patients aged
50–64 years comprised the greatest part of the IPD
population, and most of these patients had comorbid
conditions, placing them at higher risk. Further stu-
dies are indicated to evaluate the cost-effectiveness of
pneumococcal vaccination targeting adults aged 50
years and older.
Competing interest
The authors have no conflicts of interest to disclose.
Authors’ contributions
JYS and HJC participated in study design, analyzed the data and drafted the
manuscript. JYC, JSL, In-GB, YKK, JWS, YMJ, WSC, JL, KHP and WJK collected
and analyzed the data. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by a Korea University Guro Hospital grant that was
underwritten by the Pfizer.
Author details
1Division of Infectious Disease, Department of Internal Medicine, Korea
University Guro Hospital, 148 Gurodong-ro, Guro-gu, Seoul 152-703, Republic
of Korea. 2Asian Pacific Influenza Institute (APII), Seoul, Republic of Korea.
3Division of Infectious Diseases, Department of Internal Medicine, Yonsei
University College of Medicine, Yonsei, Seoul, Republic of Korea. 4Division of
Infectious Diseases, Department of Internal Medicine, Inha University School
of Medicine, Incheon, Republic of Korea. 5Division of Infectious Diseases,
Department of Internal Medicine, Gyeongsang National University School of
Medicine, Gyeongsang, Republic of Korea. 6Division of Infectious Diseases,
Department of Internal Medicine, Yonsei University, Wonju College of
Medicine, Wonju, Republic of Korea. 7Division of Infectious Disease,
Department of Internal Medicine, Korea University Anam Hospital, 73
Inchon-ro, Seongbuk-gu, Seoul 136-705, Republic of Korea. 8Division of
Infectious Diseases, Department of Internal Medicine, Konyang University
College of Medicine, Daejeon, Republic of Korea. 9Division of Infectious
Disease, Department of Internal Medicine, Korea University Ansan Hospital,
123 Jeokgeum-ro, Danwon-gu, Ansan-si, Gyeonggi-do 425-707, Republic of
Korea. 10Division of Infectious Diseases, Department of Internal Medicine,
Hallym University College of Medicine, Chuncheon, Republic of Korea.
11Division of Infectious Diseases, Department of Internal Medicine, Chonnam
National University Medical School, Gwangju, Republic of Korea.
Received: 30 December 2012 Accepted: 14 April 2013
Published: 4 May 2013
References
1. WHO: Pneumococcal conjugate vaccine for childhood immunization-
-WHO position paper. Wkly Epidemiol Rec 2007, 82(12):93–104.
2. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E,
Mulholland K, Levine OS, Cherian T: Burden of disease caused by
Streptococcus pneumoniae in children younger than 5 years: global
estimates. Lancet 2009, 374(9693):893–902.
3. Huang SS, Johnson KM, Ray GT, Wroe P, Lieu TA, Moore MR, Zell ER,
Linder JA, Grijalva CG, Metlay JP, et al: Healthcare utilization and cost
of pneumococcal disease in the United States. Vaccine 2011,
29(18):3398–3412.
4. MMWR Morbidity and mortality weekly reportUse of 13-valent
pneumococcal conjugate vaccine and 23-valent pneumococcal
polysaccharide vaccine for adults with immunocompromising
conditions: recommendations of the Advisory Committee on
Immunization Practices (ACIP). 2012, 61(40):816–819.
5. Ledwich LJ, Harrington TM, Ayoub WT, Sartorius JA, Newman ED: Improved
influenza and pneumococcal vaccination in rheumatology patients
taking immunosuppressants using an electronic health record best
practice alert. Arthritis Rheum 2009, 61(11):1505–1510.
6. Pebody RG, Hippisley-Cox J, Harcourt S, Pringle M, Painter M, Smith G:
Uptake of pneumococcal polysaccharide vaccine in at-risk populations
in England and Wales 1999–2005. Epidemiol Infect 2008, 136(3):360–369.
7. Sowden E, Mitchell WS: An audit of influenza and pneumococcal
vaccination in rheumatology outpatients. BMC Musculoskelet Disord 2007,
8:58.
8. Cho EY, Kang HM, Lee J, Kang JH, Choi EH, Lee HJ: Changes in serotype
distribution and antibiotic resistance of nasopharyngeal isolates of
Streptococcus pneumoniae from children in Korea, after optional use of
the 7-valent conjugate vaccine. J Korean Medical Sci 2012, 27(7):716–722.
9. Song JY, Cheong HJ, Heo JY, Noh JY, Seo YB, Kim IS, Choi WS, Kim WJ:
Outpatientbased pneumococcal vaccine campaign and survey of
perceptions about pneumococcal vaccination in patients and doctors.
Yonsei Med J 2013, 54:469–475.
10. Wikler MA: Clinical and Laboratory Standards Institute: Performance standards
for antimicrobial susceptibility testing: nineteenth informational supplement
Wayne. PA: Clinical and Laboratory Standards Institute; 2009.
11. Choi WS, Noh JY, Huh JY, Youn YK, Kim MJ, Jo YM, Kim JY, Song JY, Park
DW, Kim WJ, et al: Clinical features of invasive pneumococcal disease in
Korea. Infect Chemother 2009, 42(3):156–161.
Song et al. BMC Infectious Diseases 2013, 13:202 Page 8 of 9
http://www.biomedcentral.com/1471-2334/13/202
12. Laurichesse H, Romaszko JP, Nguyen LT, Souweine B, Poirier V, Guólon D,
André M, Ruivard M, De Champs C, Caillaud D, et al: Clinical characteristics
and outcome of patients with invasive pneumococcal disease,
Puy-de-Dome, France, 1994–1998. Eur J Clin Microbiol Infect Dis 2001,
20(5):299–308.
13. Weycker D, Strutton D, Edelsberg J, Sato R, Jackson LA: Clinical and
economic burden of pneumococcal disease in older US adults. Vaccine
2010, 28(31):4955–4960.
14. Jain S, Benoit SR, Skarbinski J, Bramley AM, Finelli L: Influenza-associated
pneumonia among hospitalized patients with 2009 pandemic influenza
a (H1N1) virus–United States, 2009. Clin Infect Dis 2012, 54(9):1221–1229.
15. Barahona Rondon L, Soriano Garcia F, Granizo Martinez JJ, Santos O'Connor
F, Lopez Duran JC, Fernandez Roblas R: Risk factors of mortality in invasive
pneumococcal disease. Med Clin (Barc) 2004, 123(15):575–577.
16. Kang CI, Song JH, Kim SH, Chung DR, Peck KR, Thamlikitkul V, Wang H,
So TM, Hsueh PR, Yasin RM, et al: Risk factors and pathogenic significance
of bacteremic pneumonia in adult patients with community-acquired
pneumococcal pneumonia. J Infect 2013, 66(1):34–40.
17. Jansen AG, Rodenburg GD, van der Ende A, van Alphen L, Veenhoven RH,
Spanjaard L, Sanders EA, Hak E: Invasive pneumococcal disease among
adults: associations among serotypes, disease characteristics, and
outcome. Clin Infect Dis 2009, 49(2):e23–29.
18. Sjostrom K, Spindler C, Ortqvist A, Kalin M, Sandgren A, Kuhlmann-Berenzon
S, Henriques-Normark B: Clonal and capsular types decide whether
pneumococci will act as a primary or opportunistic pathogen. Clin Infect
Dis 2006, 42(4):451–459.
19. Rodríguez MA, González AV, Gavín MA, Martínez FM, Marín NG, Blázquez BR,
Moreno JC: Invasive pneumococcal disease: association between
serotype, clinical presentation and lethality. Vaccine 2011, 29(34):5740–
5746.
20. Ritchie ND, Mitchell TJ, Evans TJ: What is different about serotype 1
pneumococci? Future microbiology 2012, 7(1):33–46.
21. Bravo LC: Overview of the disease burden of invasive pneumococcal
disease in Asia. Vaccine 2009, 27(52):7282–7291.
22. Centers for Disease Control and Prevention (CDC): Invasive pneumococcal
disease in children 5 years after conjugate vaccine introduction--eight
states, 1998–2005. MMWR Morbidity and mortality weekly report 2008,
57(6):144–148.
23. Elberse KE, van der Heide HG, Witteveen S, van de Pol I, Schot CS, van der
Ende A, Berbers GA, Schouls LM: Changes in the composition of the
pneumococcal population and in IPD incidence in The Netherlands after
the implementation of the 7-valent pneumococcal conjugate vaccine.
Vaccine 2012, 30(52):7644–7651.
24. Lee S, Lee K, Kang Y, Bae S: Prevalence of serotype and multidrug-
resistance of Streptococcus pneumoniae respiratory tract isolates in 265
adults and 36 children in Korea, 2002–2005. Microb Drug Resist 2010,
16(2):135–142.
25. Song JH, Baek JY, Cheong HS, Chung DR, Peck KR, Ko KS: Changes of
serotype and genotype in Streptococcus pneumoniae isolates from a
Korean hospital in 2007. Diagnostic microbiology and infectious disease
2009, 63(3):271–278.
doi:10.1186/1471-2334-13-202
Cite this article as: Song et al.: Clinical and economic burden of invasive
pneumococcal disease in adults: a multicenter hospital-based study.
BMC Infectious Diseases 2013 13:202.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Song et al. BMC Infectious Diseases 2013, 13:202 Page 9 of 9
http://www.biomedcentral.com/1471-2334/13/202
